Abstract:Abstract The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most commonly in EGFR -mutant non-small cell lung cancer, secondary resistance mutations on the target kinase domain emerge to diminish the binding affinity of first- and second-generation inhibitors. Other alternative resistance mechanisms include activating complementary bypass pathways and phenotypic transformation. Sequential monotherapies promise to temporarily address the problem of acquired drug resistance, but evidently are limited by the tumor cells’ ability to adapt and evolve new resistance mechanisms to persist in the drug environment. Recent studies have nominated a model of drug resistance and tumor progression under targeted therapy as a result of a small subpopulation of cells being able to endure the drug (minimal residual disease cells) and eventually develop further mutations that allow them to regrow and become the dominant population in the therapy-resistant tumor. This subpopulation of cells appears to have developed through a subclonal event, resulting in driver mutations different from the driver mutation that is tumor-initiating in the most common ancestor. As such, an understanding of intratumoral heterogeneity—the driving force behind minimal residual disease—is vital for the identification of resistance drivers that results from branching evolution. Currently available methods allow for a more comprehensive and holistic analysis of tumor heterogeneity in that issues associated with spatial and temporal heterogeneity can now be properly addressed. This review provides some background regarding intratumoral heterogeneity and how it leads to incomplete molecular response to targeted therapies, and proposes the use of single-cell methods, sequential liquid biopsy, and multiregion sequencing to discover the link between intratumoral heterogeneity and early adaptive drug resistance. In summary, minimal residual disease as a result of intratumoral heterogeneity is the earliest form of acquired drug resistance. Emerging technologies such as liquid biopsy and single-cell methods allow for studying targetable drivers of minimal residual disease and contribute to preemptive combinatorial targeting of both drivers of the tumor and its minimal residual disease cells.

A narrative review of tumor heterogeneity and challenges to tumor drug therapy

Heterogeneity in Primary Tumors and Corresponding Metastases: Could It Provide Us with Any Hints to Personalize Cancer Therapy?

Tumor Heterogeneity: The Challenge of Precision Medicine

Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance

Heterogeneity of the tumor immune microenvironment and its clinical relevance

Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy

Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance

Bladder Tumor Heterogeneity: The Impact on Clinical Treatment

Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment

From complexity to clarity: unravelling tumor heterogeneity through the lens of tumor microenvironment for innovative cancer therapy

Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications

Correction: Breast Cancer Heterogeneity and Its Implication in Personalized Precision Therapy

Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis

Lung Cancer Heterogeneity and New Strategies for Drug Therapy.

Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications

Progress in the Clinical Detection of Heterogeneity in Breast Cancer.

Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy

Tumour heterogeneity and resistance to cancer therapies

Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment